Comparison of the rapidity of SARS-CoV-2 immune responses between primary and booster vaccination for COVID-19
- Abstract
- Background/Aims: The rapidity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific memory B or T cell response in vaccinated individuals is important for our understanding of immunopathogenesis of coronavirus disease 2019 (COVID-19). We therefore compared the timing of adequate immune responses between the first and booster doses of COVID-19 vaccines in infection-naïve healthcare workers.
Methods: We enrolled healthcare workers who received two doses of either the BNT162b2 vaccine or the ChAdOx1 vaccine, all of whom received the BNT162b2 vaccine as the booster (the third) dose. Spike 1 (S1)-immunoglobulin G (IgG) antibodies and interferon gamma producing T cell responses were measured at 0, 7, 14, and 21 days after the first dose, and at 0 and between 2 to 7 days after the booster dose.
Results: After the first-dose vaccination, the S1-IgG antibody responses were elicited within 14 days in the BNT162b2 group and within 21 days in the ChAdOx1 group. After the booster dose, the S1-IgG antibody responses were elicited within 5 days in both groups. The SARS-CoV-2-specific T cell responses appeared at 7 days after the first dose and at 4 days after the booster dose.
Conclusions: SARS-CoV-2-specific immune responses by memory B cells and T cells may be expected to appear around 4 to 5 days after the booster dose.
- Author(s)
- Ji Yeun Kim; Ji-Soo Kwon; Hye Hee Cha; So Yun Lim; Seongman Bae; Sung-Han Kim
- Issued Date
- 2022
- Type
- Article
- Keyword
- Antibody formation; Primary; Secondary; COVID-19 vaccines
- DOI
- 10.3904/kjim.2022.173
- URI
- https://oak.ulsan.ac.kr/handle/2021.oak/14338
- Publisher
- Korean Journal of Internal Medicine
- Language
- 한국어
- ISSN
- 1226-3303
- Citation Volume
- 37
- Citation Number
- 6
- Citation Start Page
- 1234
- Citation End Page
- 1240
-
Appears in Collections:
- Medicine > Nursing
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.